Osimertinib for Secondary T790M-Mutation-Positive Squamous Cell Carcinoma Transformation After Afatinib Failure

J Thorac Oncol. 2018 Dec;13(12):e252-e254. doi: 10.1016/j.jtho.2018.07.100.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acrylamides / therapeutic use*
  • Afatinib / pharmacology*
  • Aniline Compounds / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / genetics
  • Carcinoma, Squamous Cell / pathology
  • Drug Resistance, Neoplasm / genetics
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Middle Aged
  • Mutation*
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use
  • Salvage Therapy*

Substances

  • Acrylamides
  • Aniline Compounds
  • Protein Kinase Inhibitors
  • osimertinib
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors